Key Studies Influencing My Practice Following EACS 2021

October 27-30, 2021; London, United Kingdom
Read expert faculty members’ summaries of key studies from EACS 2021, including results from studies on BIC/FTC/TAF in a test-and-treat model; islatravir and doravirine in treatment naïve patients; DTG/3TC in patients with an M184V mutation; long-acting CAB + RPV by BMI category, patient satisfaction, and outcomes after discontinuation; lenacapavir in heavily treatment experienced patients; and COVID-19 vaccine effectiveness and the impact of the pandemic on virologic suppression in PWH.
person default
Tristan J. Barber, MA, MD, FRCP
Chloe Orkin Photo
Chloe Orkin, MBChB, FRCP, MD
Jürgen K. Rockstroh, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 697 KB
Released: November 15, 2021


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email:

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

Slides from CCO: Discussion of the implications and considerations of polypharmacy and cardiovascular risk on choice of ART in older PWH

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: November 29, 2021

Commentary from Dr Jason Halperin on the use of 2-drug ART for rapid start, from Clinical Care Options (CCO)

Jason Halperin, MD, MPH Released: November 29, 2021

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for patients with virologic failure and resistance

W. David Hardy, MD Josep M. Llibre, MD, PhD Released: November 29, 2021

Perspective on ART modification to reduce CVD risk in PWH, from Dr Jens D. Lundgren and Clinical Care Options (CCO)

Jens D. Lundgren, MD, DMSc Released: November 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.